Development of Neutralizing Monoclonal Antibodies for Oncogenic HPV Types 31, 33, 45, 52, and 58.

Clinical and vaccine immunology : CVI

PubMedID: 24574536

Brown MJ, Seitz H, Towne V, Müller M, Finnefrock AC. Development of Neutralizing Monoclonal Antibodies for Oncogenic HPV Types 31, 33, 45, 52, and 58. Clin Vaccine Immunol. 2014;.
Human Papillomavirus (HPV) is the etiological agent for all cervical cancers, a significant number of other anogenital cancers, and a growing number of head-and-neck cancers. Two licensed vaccines offer protection against the most prevalent oncogenic types, 16 and 18, responsible for approximately 70% of cervical cancer cases worldwide and one of these also offers protection against types 6 and 11, responsible for 90% of genital warts. The vaccines are comprised of recombinantly expressed major capsid proteins that self-assemble into virus-like particles (VLPs) and prevent infection by elicting neutralizing antibodies. Adding the other frequently identified oncogenic types 31, 33, 45, 52, and 58 to a vaccine would increase the coverage against HPV-induced cancers to approximately 90%. We describe the generation and characterization of panels of monoclonal antibodies to these five additional oncogenic HPV types, and the selection of antibody pairs that were high affinity, type-specific, and recognized conformation-dependent neutralizing epitopes. Such characteristics make these antibodies useful tools for monitoring the production and potency of a prototype vaccine as well as monitoring vaccine-induced immune response in the clinic.